Annals of Nuclear Medicine最新文献

{"title":"Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer","authors":"Yoichi Shimizu,&nbsp;Masato Ando,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono","doi":"10.1007/s12149-024-01959-9","DOIUrl":"10.1007/s12149-024-01959-9","url":null,"abstract":"<div><h3>Objective</h3><p>Prostate-specific membrane antigen (PSMA) is a well-known biomarker of prostate cancer. Previously, our group reported that the succinimidyl–cystatin–urea–glutamate (SCUE) moiety has a high affinity for PSMA. In this study, we developed the novel technetium-99m-labeled PSMA-targeting probe “[^99mTc]Tc-(Ham-SCUE)₂” based on a hydroxamamide chelate with a bivalent SCUE and evaluated its potential as a SPECT imaging probe for the diagnosis of PSMA-expressing prostate cancer.</p><h3>Methods</h3><p>Ham-SCUE was synthesized by a one-step reaction with Ham-Mal and cysteine-urea-glutamine. Then, Ham-SCUE was reacted with [^99mTc]NaTcO₄ for 10 min at room temperature to obtain [^99mTc]Tc-(Ham-SCUE)₂. [^99mTc]Tc-(Ham-SCUE)₂ was added to LNCaP (high PSMA expression) cells or PC3 (low PSMA expression) cells, and their radioactivity was measured 60 min after administration. The blocking study was performed by co-incubation of LNCaP cells with various concentrations of 2-PMPA (a PSMA inhibitor) for 15 min before adding [^99mTc]Tc-(Ham-SCUE)₂. The biodistribution of [^99mTc]Tc-(Ham-SCUE)₂ in LNCaP/PC3 dual xenografted C.B.-17/Icr scid/scid Jcl mice was evaluated for 120 min after intravenous injection. The blocking study was performed by pretreatment of mice with 2-PMPA (10 mg/kg weight).</p><h3>Results</h3><p>[^99mTc]Tc-(Ham-SCUE)₂ was acquired at radiochemical yields of 56% with a radiochemical purity of over 95%. The cellular uptake level of [^99mTc]Tc-(Ham-SCUE)₂ by LNCaP cells was significantly higher than that by PC3 cells (LNCaP: 11.12 ± 0.71 vs. PC3: 1.40 ± 0.13%uptake/mg protein, <i>p</i> &lt; 0.01), and the uptake was significantly suppressed by pretreatment with 2-PMPA (2.56 ± 0.37%uptake/mg protein, <i>p</i> &lt; 0.05). IC₅₀ of 2-PMPA was 245 ± 47 nM. In the in vivo study, the radioactivity of LNCaP tumor tissue was significantly higher than that of PC3 tumor tissue at 120 min after the administration of [^99mTc]Tc-(Ham-SCUE)₂ (LNCaP: 9.97 ± 2.79, PC3: 1.16 ± 0.23%ID/g, <i>p</i> &lt; 0.01), and was suppressed by pretreatment with 2-PMPA (2.50 ± 0.45%ID/g, <i>p</i> &lt; 0.01).</p><h3>Conclusion</h3><p>[^99mTc]Tc-(Ham-SCUE)₂ has the potential to be a SPECT imaging agent for diagnosing high PSMA-expressing prostate cancer.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"847 - 851"},"PeriodicalIF":2.5,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map","authors":"Chio Okuyama,&nbsp;Tatsuya Higashi,&nbsp;Koichi Ishizu,&nbsp;Naoya Oishi,&nbsp;Kuninori Kusano,&nbsp;Miki Ito,&nbsp;Shinya Kagawa,&nbsp;Tomoko Okina,&nbsp;Norio Suzuki,&nbsp;Hiroshi Hasegawa,&nbsp;Yasuhiro Nagahama,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono,&nbsp;Hiroshi Yamauchi","doi":"10.1007/s12149-024-01956-y","DOIUrl":"10.1007/s12149-024-01956-y","url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to assess the utility of newly developed objective methods for the evaluation of intracranial abnormal amyloid deposition using PET/CT histogram without use of cortical ROI analyses.</p><h3>Methods</h3><p>Twenty-five healthy volunteers (HV) and 38 patients with diagnosed or suspected dementia who had undergone ¹⁸F-FPYBF-2 PET/CT were retrospectively included in this study. Out of them, ¹¹C-PiB PET/CT had been also performed in 13 subjects. In addition to the conventional methods, namely visual judgment and quantitative analyses using composed standardized uptake value ratio (comSUVR), the PET images were also evaluated by the following new parameters: the skewness and the mode-to-mean ratio (MMR) obtained from the histogram of the brain parenchyma; Top20%-map highlights the areas with high tracer accumulation occupying 20% volume of the total brain parenchymal on the individual’s CT images. We evaluated the utility of the new methods using histogram compared with the visual assessment and comSUVR. The results of these new methods between ¹⁸F-FPYBF-2 and ¹¹C-PiB were also compared in 13 subjects.</p><h3>Results</h3><p>In visual analysis, 32, 9, and 22 subjects showed negative, border, and positive results, and composed SUVR in each group were 1.11 ± 0.06, 1.20 ± 0.13, and 1.48 ± 0.18 (<i>p</i> &lt; 0.0001), respectively. Visually positive subjects showed significantly low skewness and high MMR (<i>p</i> &lt; 0.0001), and the Top20%-Map showed the presence or absence of abnormal deposits clearly. In comparison between the two tracers, visual evaluation was all consistent, and the ComSUVR, the skewness, the MMR showed significant good correlation. The Top20%-Maps showed similar pattern.</p><h3>Conclusions</h3><p>Our new methods using the histogram of the brain parenchymal accumulation are simple and suitable for clinical practice of amyloid PET, and Top20%-Map on the individual’s brain CT can be of great help for the visual assessment.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 9","pages":"763 - 773"},"PeriodicalIF":2.5,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential centiloid scale normalization techniques: comparison between hybrid PET/MRI and independently acquired MRI","authors":"Ryo Yamakuni,&nbsp;Takenobu Murakami,&nbsp;Naoyuki Ukon,&nbsp;Takeyasu Kakamu,&nbsp;Wataru Toda,&nbsp;Kasumi Hattori,&nbsp;Hirofumi Sekino,&nbsp;Shiro Ishii,&nbsp;Kenji Fukushima,&nbsp;Hiroshi Matsuda,&nbsp;Yoshikazu Ugawa,&nbsp;Noritaka Wakasugi,&nbsp;Mitsunari Abe,&nbsp;Hiroshi Ito","doi":"10.1007/s12149-024-01955-z","DOIUrl":"10.1007/s12149-024-01955-z","url":null,"abstract":"<div><h3>Objective</h3><p>Centiloid (CL) scales play an important role in semiquantitative analyses of amyloid-β (Aβ) PET. CLs are derived from the standardized uptake value ratio (SUVR), which needs Aβ positron emission tomography (PET) normalization processing. There are two methods to collect the T1-weighted imaging (T1WI) for normalization: (i) anatomical standardization using simultaneously acquired T1WI (PET/MRI), usually adapted to PET images from PET/MRI scanners, and (ii) T1WI from a separate examination (PET + MRI), usually adapted to PET images from PET/CT scanners. This study aimed to elucidate the correlations and differences in CLs between when using the above two T1WI collection methods.</p><h3>Methods</h3><p>Among patients who underwent Aβ PET/MRI (using ¹¹C-Pittuberg compound B (¹¹C-PiB) or ¹⁸F‐flutemetamol (¹⁸F-FMM)) at our institution from 2015 to 2023, we selected 49 patients who also underwent other additional MRI examinations, including T1WI for anatomic standardization within 3 years. Thirty-one of them underwent ¹¹C‐PiB PET/MRI, and 18 participants underwent ¹⁸F‐FMM PET/MRI. Twenty-five of them, additional MRI acquisition parameters were identical to simultaneous MRI during PET, and 24 participants were different. After normalization using PET/MRI or PET + MRI method each, SUVR was measured using the Global Alzheimer’s Association Initiative Network cerebral cortical and striatum Volume of Interest templates (VOI) and whole cerebellum VOI. Subsequently, CLs were calculated using the previously established equations for each Aβ PET tracer.</p><h3>Results</h3><p>Between PET/MRI and PET + MRI methods, CLs correlated linearly in ¹¹C-PiB PET (<i>y</i> = 1.00<i>x</i> – 0.11, <i>R</i>² = 0.999), ¹⁸F-FMM PET (<i>y</i> = 0.97<i>x</i> – 0.12, 0.997), identical additional MRI acquisition (<i>y</i> = 1.00<i>x</i> + 0.33, 0.999), different acquisition (<i>y</i> = 0.98<i>x</i> – 0.43, 0.997), and entire study group (<i>y</i> = 1.00<i>x</i> – 0.24, 0.999). Wilcoxon signed-rank test revealed no significant differences: ¹¹C-PiB (<i>p</i> = 0.49), ¹⁸F-FMM (0.08), and whole PET (0.46). However, significant differences were identified in identical acquisition (<i>p</i> = 0.04) and different acquisition (<i>p</i> = 0.02). Bland–Altman analysis documented only a small bias between PET/MRI and PET + MRI in ¹¹C‐PiB PET, ¹⁸F‐FMM PET, identical additional MRI acquisition, different acquisition, and whole PET (– 0.05, 0.67, – 0.30, 0.78, and 0.21, respectively).</p><h3>Conclusions</h3><p>Anatomical standardizations using PET/MRI and using PET + MRI can lead to almost equivalent CL. The CL values obtained using PET/MRI or PET + MRI normalization methods are consistent and comparable in clinical studies.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"835 - 846"},"PeriodicalIF":2.5,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Annals of Nuclear Medicine","authors":"","doi":"10.1007/s12149-024-01953-1","DOIUrl":"10.1007/s12149-024-01953-1","url":null,"abstract":"","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"586 - 586"},"PeriodicalIF":2.5,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Novel indices representing heterogeneous distributions of myocardial perfusion imaging","authors":"Misato Chimura,&nbsp;Tomohito Ohtani,&nbsp;Fusako Sera,&nbsp;Rie Higuchi,&nbsp;Kenji Kajitani,&nbsp;Kenichi Nakajima,&nbsp;Yasushi Sakata","doi":"10.1007/s12149-024-01951-3","DOIUrl":"10.1007/s12149-024-01951-3","url":null,"abstract":"","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"584 - 585"},"PeriodicalIF":2.5,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11217040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?","authors":"İhsan Kaplan,&nbsp;Halil Kömek,&nbsp;Canan Can,&nbsp;Nadiye Akdeniz,&nbsp;Yunus Güzel,&nbsp;Ferat Kepenek,&nbsp;Ayhan Şenol,&nbsp;Serdar İleri,&nbsp;Hüseyin Karaoğlan,&nbsp;İhsan Solmaz,&nbsp;Mehmet Serdar Yıldırım,&nbsp;Veysi Şenses,&nbsp;Fulya Kaya,&nbsp;Cihan Gündoğan","doi":"10.1007/s12149-024-01954-0","DOIUrl":"10.1007/s12149-024-01954-0","url":null,"abstract":"<div><h3>Purpose</h3><p>The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0.</p><h3>Materials and methods</h3><p>This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [¹⁸F]FDG PET/CT images and whose [¹⁸F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient.</p><h3>Results</h3><p>The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (<i>p</i> &lt; 0.001, <i>p</i> = 0.006, <i>p</i> = 0.003, and <i>p</i> = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively.</p><h3>Conclusion</h3><p>The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"825 - 834"},"PeriodicalIF":2.5,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inverse correlation between age of onset and myocardial amyloid deposition quantified by 99mTc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy","authors":"Hiroshi Kanaya,&nbsp;Shinya Shiraishi,&nbsp;Kouji Ogasawara,&nbsp;Koya Iwashita,&nbsp;Fumi Sakamoto,&nbsp;Seiji Takashio,&nbsp;Yoshiki Mikami,&nbsp;Kenichi Tsujita,&nbsp;Toshinori Hirai","doi":"10.1007/s12149-024-01943-3","DOIUrl":"10.1007/s12149-024-01943-3","url":null,"abstract":"<div><h3>Objective</h3><p>Wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM) is increasingly recognized as a contributing factor to cardiac insufficiency in the elderly population. We aimed to identify the factors affecting age of onset of ATTRwt-CM, encompassing the assessment of amyloid deposition in myocardial tissue through the use of ^99mTc-pyrophosphate (PYP) and clinical parameters.</p><h3>Methods</h3><p>A retrospective investigation involving a consecutive cohort of 107 cases, each having been diagnosed with ATTRwt-CM confirmed through histopathological and genetic analysis, was performed. All patients underwent PYP scintigraphy, and the heart-to-contralateral (H/CL) ratio was calculated to measure amyloid deposition in the myocardium. Univariate and multivariate analyses were performed to identify independent predictors of the age of onset of ATTRwt-CM, considering the H/CL ratio and various clinical risk factors for heart failure.</p><h3>Results</h3><p>Gender (<i>p = </i>0.03), Creatinine (Cr) (<i>r = </i>0.32, p &lt; 0.01), hemoglobin (Hb) (<i>r = </i> − 0.44, <i>p &lt; </i>0.01), albumin (Alb) (<i>r = </i> − 0.32, <i>p &lt; </i>0.01), brain natriuretic peptide (BNP) (<i>r = </i>0.21, <i>p = </i>0.03), low-density lipoprotein-cholesterol (LDL-C) (<i>r = </i> − 0.27, <i>p &lt; </i>0.01), and H/CL ratio (<i>r = </i> − 0.44, <i>p &lt; </i>0.01) were all significantly associated with the onset age. In multiple regression analysis, the independent predictive factors for the onset age of ATTRwt-CM were identified as the H/CL ratio (<i>p &lt; </i>0.01), Hb (<i>p &lt; </i>0.01), and Cr (<i>p &lt; </i>0.01).</p><h3>Conclusion</h3><p>The H/CL ratio, Hb, and Cr independently affect age of onset in patients with ATTRwt-CM. The H/CL ratio is inversely correlated with age of onset, and may be the sole factor in the development of heart failure in early onset patients, while it may have a synergistic effect on heart failure with anemia and renal dysfunction in late-onset patients.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 9","pages":"744 - 753"},"PeriodicalIF":2.5,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma","authors":"Huan Liang,&nbsp;Weilin Tan,&nbsp;Jie Wang,&nbsp;Mengdan Li,&nbsp;Hua Pang,&nbsp;Xiaohui Wang,&nbsp;Lu Yang,&nbsp;Xingguo Jing","doi":"10.1007/s12149-024-01949-x","DOIUrl":"10.1007/s12149-024-01949-x","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to develop a novel prediction model and risk stratification system that could accurately predict progression-free survival (PFS) in patients with nasopharyngeal carcinoma (NPC).</p><h3>Methods</h3><p>Herein, we included 106 individuals diagnosed with NPC, who underwent ¹⁸F-FDG PET/CT scanning before treatment. They were divided into training (<i>n</i> = 76) and validation (<i>n</i> = 30) sets. The prediction model was constructed based on multivariate Cox regression analysis results and its predictive performance was evaluated. Risk factor stratification was performed based on the nomogram scores of each case, and Kaplan–Meier curves were used to evaluate the model’s discriminative ability for high- and low-risk groups.</p><h3>Results</h3><p>Multivariate Cox regression analysis showed that N stage, M stage, SUV_max, MTV, HI, and SIRI were independent factors affecting the prognosis of patients with NPC. In the training set, the model considerably outperformed the TNM stage in predicting PFS (AUCs of 0.931 vs. 0.841, 0.892 vs. 0.785, and 0.892 vs. 0.804 at 1–3 years, respectively). The calibration plots showed good agreement between actual observations and model predictions. The DCA curves further justified the effectiveness of the model in clinical practice. Between high- and low-risk group, 3-year PFS rates were significantly different (high- vs. low-risk group: 62.8% vs. 9.8%, <i>p</i> &lt; 0.001). Adjuvant chemotherapy was also effective for prolonging survival in high-risk patients (<i>p</i> = 0.009).</p><h3>Conclusion</h3><p>Herein, a novel prediction model was successfully developed and validated to improve the accuracy of prognostic prediction for patients with NPC, with the aim of facilitating personalized treatment.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"802 - 813"},"PeriodicalIF":2.5,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation on low-iodine diet implementation by medical staff before radioactive iodine treatment for differentiated thyroid carcinoma","authors":"Yupin Yi,&nbsp;Yuquan Zhu,&nbsp;Youfeng Wu,&nbsp;Fengqiong Hu","doi":"10.1007/s12149-024-01952-2","DOIUrl":"10.1007/s12149-024-01952-2","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the implementation of low-iodine diets by medical staff caring for patients with differentiated thyroid carcinoma prior to ¹³¹I therapy across 58 hospitals, and offer valuable insights for the development of guidelines on low-iodine diets.</p><h3>Methods</h3><p>Convenience sampling was utilized to conduct a survey among 163 medical staff members working in nuclear medicine departments across 58 tertiary hospitals using a self-designed questionnaire.</p><h3>Results</h3><p>Concerning the duration of the low-iodine diet prior to treatment, the medical staff’s recommendations were as follows: 58.28% suggested 2–4 weeks, 31.29% recommended more than 4 weeks, 9.2% opted for 7–13 days, and 1.23% favored less than 1 week. Regarding the timing of resuming a normal diet, the respondents’ recommendations ranged from immediately after treatment (1.84%) to 3 months post-treatment (8.58%), with intermediate recommendations of 2 h (8.58%), 24–48 h (14.11%), post-discharge (12.26%), and 1 month (42.94%). Furthermore, the surveyed medical staff unanimously recommended abstaining from seafood, with 90.8% also advising against the consumption of iodized salt, 91.41% recommending avoidance of iodine-containing medications, and 71.17% advising caution with moderately high-iodine foods. Notably, 75.46% of the medical staff evaluated patient compliance with the low-iodine diet. When patients failed to adhere to the diet preparation, 33.74% of healthcare workers chose to proceed with treatment. In terms of guidance sources, 96.93% of respondents relied on relevant guidelines, 66.26% referred to the literature, and 49.69% drew upon their clinical experience. During hospitalization, 58.28% of the medical staff continued to guide patients on the low-iodine diet, while only 8.59% provided such guidance after discharge. Notably, only 20.25% of the staff considered consulting the nutrition department.</p><h3>Conclusion</h3><p>This study underscored substantial variations in the duration and selection criteria for low-iodine diets, which were linked to a scarcity of standardized evaluations. Consequently, there is an urgent need for further research to establish detailed, practical, accessible, comprehensive, and dependable implementation programs for low-iodine diets.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"639 - 646"},"PeriodicalIF":2.5,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging","authors":"Kenichi Nakajima,&nbsp;Takeshi Matsumura,&nbsp;Junji Komatsu,&nbsp;Hiroshi Wakabayashi,&nbsp;Kenjiro Ono,&nbsp;Seigo Kinuya","doi":"10.1007/s12149-024-01950-4","DOIUrl":"10.1007/s12149-024-01950-4","url":null,"abstract":"<div><h3>Objective</h3><p>We aimed to establish a practical diagnostic index for Lewy body diseases (LBD), such as Parkinson’s disease and dementia, with Lewy bodies in outpatient settings and criteria for exempting patients from late imaging.</p><h3>Methods</h3><p>We acquired early and late ¹²³I-metaiodobenzylguanidine (MIBG) images from 108 consecutive patients with suspected LBD and standardized heart-to-mediastinum (H/M) ratios for collimator conditions. Exclusions included young-onset Parkinson’s disease (age &lt; 50 years) and genetic transthyretin-type amyloidosis. We developed logistic models incorporating H/M ratios with or without age (<i>n</i> = 92). The sympathetic MIBG index for LBD (SMILe index), categorized LBD likelihood from 0 (lowest) to 1 (highest). Diagnostic accuracy was assessed as the area under the receiver operating characteristic (ROC) curve (AUC). The characteristics of the new index were compared with H/M ratios. The need for late imaging was explored using the SMILe index.</p><h3>Results</h3><p>Early or late SMILe indexes using a single H/M ratio variable discriminated LBD from non-LBD. The AUC values for early and late SMILe indexes were 0.880 and 0.894 (<i>p</i> &lt; 0.0001 for both), identical to those for early and late H/M ratios. The sensitivity and the specificity of early SMILe indexes with a 0.5 threshold were 76% and 90%, achieving accuracy of accuracy 86%. Similarly, the late SMILe index demonstrated a sensitivity of 76% and specificity of 87%, with an accuracy of 84%. Early SMILe indexes &lt; 0.3 or &gt; 0.7 (representing 84% patients) indicated a diagnosis without a late MIBG study.</p><h3>Conclusion</h3><p>The ¹²³I-MIBG-derived SMILe indexes provide likelihood of LBD, and those with a 50% threshold demonstrated optimal diagnostic accuracy for LBD. The index values of either &lt; 0.3 or &gt; 0.7 accurately selected patients who do not need late imaging.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"814 - 824"},"PeriodicalIF":2.5,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}